VEGF	0	4	B-Gene_or_gene_product
,	4	5	O
angiopoietin	6	18	B-Gene_or_gene_product
-	18	19	I-Gene_or_gene_product
1	19	20	I-Gene_or_gene_product
and	21	24	O
-	25	26	B-Gene_or_gene_product
2	26	27	I-Gene_or_gene_product
in	28	30	O
bronchial	31	40	O
asthma	41	47	O
:	47	48	O
new	49	52	O
molecular	53	62	O
targets	63	70	O
in	71	73	O
airway	74	80	O
angiogenesis	81	93	O
and	94	97	O
microvascular	98	111	B-Multi-tissue_structure
remodeling	112	122	O
.	122	123	O

Airway	125	131	O
angiogenesis	132	144	O
and	145	148	O
microvascular	149	162	B-Multi-tissue_structure
remodeling	163	173	O
are	174	177	O
known	178	183	O
features	184	192	O
of	193	195	O
bronchial	196	205	O
asthma	206	212	O
,	212	213	O
but	214	217	O
the	218	221	O
mechanisms	222	232	O
of	233	235	O
these	236	241	O
structural	242	252	O
alterations	253	264	O
are	265	268	O
just	269	273	O
beginning	274	283	O
to	284	286	O
be	287	289	O
elucidated	290	300	O
.	300	301	O

Vascular	302	310	B-Gene_or_gene_product
endothelial	311	322	I-Gene_or_gene_product
growth	323	329	I-Gene_or_gene_product
factor	330	336	I-Gene_or_gene_product
(	337	338	O
VEGF	338	342	B-Gene_or_gene_product
)	342	343	O
,	343	344	O
one	345	348	O
of	349	351	O
the	352	355	O
most	356	360	O
potent	361	367	O
angiogenic	368	378	O
factors	379	386	O
,	386	387	O
stimulates	388	398	O
endothelial	399	410	B-Cell
cell	411	415	I-Cell
proliferation	416	429	O
and	430	433	O
induces	434	441	O
the	442	445	O
angiogenesis	446	458	O
.	458	459	O

Recently	460	468	O
,	468	469	O
considerable	470	482	O
attentions	483	493	O
have	494	498	O
been	499	503	O
devoted	504	511	O
to	512	514	O
the	515	518	O
physiological	519	532	O
roles	533	538	O
of	539	541	O
angiopoietin	542	554	B-Gene_or_gene_product
(	555	556	I-Gene_or_gene_product
Ang	556	559	I-Gene_or_gene_product
)	559	560	I-Gene_or_gene_product
-	560	561	I-Gene_or_gene_product
1	561	562	I-Gene_or_gene_product
and	563	566	O
-	567	568	B-Gene_or_gene_product
2	568	569	I-Gene_or_gene_product
as	570	572	O
regulatory	573	583	O
factors	584	591	O
of	592	594	O
VEGF	595	599	B-Gene_or_gene_product
.	599	600	O

Ang	601	604	B-Gene_or_gene_product
-	604	605	I-Gene_or_gene_product
1	605	606	I-Gene_or_gene_product
has	607	610	O
been	611	615	O
shown	616	621	O
to	622	624	O
induce	625	631	O
the	632	635	O
migration	636	645	O
and	646	649	O
sprouting	650	659	O
of	660	662	O
endothelial	663	674	B-Cell
cells	675	680	I-Cell
,	680	681	O
and	682	685	O
coexpression	686	698	O
of	699	701	O
Ang	702	705	B-Gene_or_gene_product
-	705	706	I-Gene_or_gene_product
1	706	707	I-Gene_or_gene_product
and	708	711	O
VEGF	712	716	B-Gene_or_gene_product
enhanced	717	725	O
angiogenesis	726	738	O
.	738	739	O

In	740	742	O
the	743	746	O
presence	747	755	O
of	756	758	O
high	759	763	O
levels	764	770	O
of	771	773	O
VEGF	774	778	B-Gene_or_gene_product
,	778	779	O
Ang	780	783	B-Gene_or_gene_product
-	783	784	I-Gene_or_gene_product
2	784	785	I-Gene_or_gene_product
also	786	790	O
promotes	791	799	O
rapid	800	805	O
increase	806	814	O
in	815	817	O
capillary	818	827	B-Tissue
diameter	828	836	O
,	836	837	O
remodeling	838	848	O
of	849	851	O
the	852	855	O
basal	856	861	B-Cellular_component
lamina	862	868	I-Cellular_component
,	868	869	O
proliferation	870	883	O
and	884	887	O
migration	888	897	O
of	898	900	O
endothelial	901	912	B-Cell
cells	913	918	I-Cell
,	918	919	O
and	920	923	O
stimulates	924	934	O
sprouting	935	944	O
of	945	947	O
new	948	951	O
blood	952	957	B-Multi-tissue_structure
vessels	958	965	I-Multi-tissue_structure
.	965	966	O

Thus	967	971	O
,	971	972	O
VEGF	973	977	B-Gene_or_gene_product
,	977	978	O
Ang	979	982	B-Gene_or_gene_product
-	982	983	I-Gene_or_gene_product
1	983	984	I-Gene_or_gene_product
and	985	988	O
-	989	990	B-Gene_or_gene_product
2	990	991	I-Gene_or_gene_product
may	992	995	O
play	996	1000	O
complementary	1001	1014	O
and	1015	1018	O
coordinated	1019	1030	O
roles	1031	1036	O
in	1037	1039	O
airway	1040	1046	O
angiogenesis	1047	1059	O
and	1060	1063	O
microvascular	1064	1077	B-Multi-tissue_structure
remodeling	1078	1088	O
,	1088	1089	O
and	1090	1093	O
these	1094	1099	O
structural	1100	1110	O
changes	1111	1118	O
are	1119	1122	O
potentially	1123	1134	O
reversible	1135	1145	O
by	1146	1148	O
therapeutic	1149	1160	O
intervention	1161	1173	O
.	1173	1174	O

The	1175	1178	O
scope	1179	1184	O
of	1185	1187	O
the	1188	1191	O
present	1192	1199	O
review	1200	1206	O
is	1207	1209	O
to	1210	1212	O
discuss	1213	1220	O
from	1221	1225	O
a	1226	1227	O
clinical	1228	1236	O
point	1237	1242	O
of	1243	1245	O
view	1246	1250	O
the	1251	1254	O
potential	1255	1264	O
interactions	1265	1277	O
between	1278	1285	O
VEGF	1286	1290	B-Gene_or_gene_product
and	1291	1294	O
angiopoietins	1295	1308	B-Gene_or_gene_product
in	1309	1311	O
the	1312	1315	O
asthmatic	1316	1325	O
airways	1326	1333	O
,	1333	1334	O
and	1335	1338	O
focus	1339	1344	O
on	1345	1347	O
the	1348	1351	O
therapeutic	1352	1363	O
implications	1364	1376	O
targeting	1377	1386	O
for	1387	1390	O
these	1391	1396	O
angiogenic	1397	1407	O
factors	1408	1415	O
.	1415	1416	O

Recently	1417	1425	O
,	1425	1426	O
there	1427	1432	O
is	1433	1435	O
an	1436	1438	O
increasing	1439	1449	O
number	1450	1456	O
of	1457	1459	O
patents	1460	1467	O
which	1468	1473	O
have	1474	1478	O
been	1479	1483	O
focused	1484	1491	O
on	1492	1494	O
the	1495	1498	O
inhibitors	1499	1509	O
of	1510	1512	O
VEGF	1513	1517	B-Gene_or_gene_product
action	1518	1524	O
.	1524	1525	O

These	1526	1531	O
inhibitors	1532	1542	O
are	1543	1546	O
directed	1547	1555	O
towards	1556	1563	O
the	1564	1567	O
receptors	1568	1577	O
of	1578	1580	O
VEGF	1581	1585	B-Gene_or_gene_product
or	1586	1588	O
intracellular	1589	1602	O
substrates	1603	1613	O
for	1614	1617	O
the	1618	1621	O
receptors	1622	1631	O
.	1631	1632	O

We	1633	1635	O
will	1636	1640	O
also	1641	1645	O
discuss	1646	1653	O
several	1654	1661	O
patents	1662	1669	O
regarding	1670	1679	O
inhibitors	1680	1690	O
of	1691	1693	O
VEGF	1694	1698	B-Gene_or_gene_product
action	1699	1705	O
in	1706	1708	O
the	1709	1712	O
present	1713	1720	O
review	1721	1727	O
.	1727	1728	O

